Refine by
Intensive Hand Care Articles & Analysis: Older
84 news found
CDC warns that those most at risk of infection include patients in hospitals, especially those who: are on breathing machines have devices such as catheters have open wounds from surgery are in intensive care units “Microorganisms have always presented a challenge to healthcare providers. ...
Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are on breathing machines · have devices such as catheters · have open wounds from surgery · are in intensive care units · have prolonged hospital stays Infections of the blood, ...
Summary The SurgiCam® HD, a specialized point-of-view camera designed for clinicians, plays a pivotal role in the documentation, education, and analysis of surgical, dental, and veterinary procedures. Its high-quality image and video capturing capabilities make it an indispensable tool in these fields. This innovative camera significantly enhances surgical practices, education, and research ...
Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are on breathing machines · have devices such as catheters · have open wounds from surgery · are in intensive care units · have prolonged hospital stays “As recently as 2017, ...
Recently, the Ministry of Industry and Information Technology, the National Health Commission and other 17 departments jointly issued the "robot" application action implementation plan to encourage the development of surgery, auxiliary examination, auxiliary rounds, intensive care, rehabilitation and other medical robot products, "robot The "robot" has ushered in a new round of development ...
Airfinity has updated its cases and deaths forecast for China’s COVID-19 outbreak as the Lunar New Year holiday hastens the spread of the virus. Today’s new forecast considers reports that some provinces including Henan, Gansu, Qinghai and Yunnan have already seen infections peak. Our analytics indicators suggest that the virus has spread more quickly to rural areas, partly driven ...
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and a patented intuitive display of contextual patient data for more efficient, actionable clinical decisions. As part of the recently ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...
Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. CytoSorbents will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021. Dr. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the ...
Researchers in London, Ont., are the first in the world to use a new device for feeding tube insertion that can improve patient safety and reduce the cost of health-care services. A team from Lawson Health Research Institute has partnered with CoapTech LLC, a medical device company, to study the use of the PUMA-G System. In October of last year, the medical and research teams were the first in ...
ByCoapTech
The company mission is to “improve patient care and safety by supplying innovative Medtech solutions inspired by clinicians and developed in partnership with the ...
ByMedovate
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance ...
Hyperfine, Inc. (Nasdaq:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, is proud to announce that Queen’s University and Kingston Health Sciences Centre are deploying a Swoop system as part of their health services benefitting six communities located in the James Bay and Hudson Bay Area. Until now, patients needing routine or ...
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...